GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 5,278 Shares

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 5,278 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $93.00, for a total transaction of $490,854.00. Following the transaction, the chief financial officer owned 3,392 shares of the company's stock, valued at approximately $315,456. This trade represents a 60.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, July 1st, Kevin Feeley sold 1,344 shares of GeneDx stock. The stock was sold at an average price of $91.12, for a total transaction of $122,465.28.
• On Monday, June 2nd, Kevin Feeley sold 370 shares of GeneDx stock. The shares were sold at an average price of $71.26, for a total value of $26,366.20.
• On Tuesday, April 29th, Kevin Feeley sold 388 shares of GeneDx stock. The shares were sold at an average price of $113.09, for a total transaction of $43,878.92.

GeneDx Price Performance

WGS stock traded down $4.35 during mid-day trading on Friday, reaching $82.56. 888,073 shares of the company's stock were exchanged, compared to its average volume of 825,253. The stock's 50 day moving average is $73.18 and its 200 day moving average is $82.65. GeneDx Holdings Corp. has a 12-month low of $25.32 and a 12-month high of $117.75. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -58.55 and a beta of 2.01. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.25 and a quick ratio of 3.07.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.11 by $0.17. The firm had revenue of $87.12 million during the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a positive return on equity of 10.17% and a negative net margin of 11.69%. On average, research analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Wall Street Analyst Weigh In

WGS has been the topic of a number of research analyst reports. Wall Street Zen raised shares of GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Piper Sandler initiated coverage on GeneDx in a research note on Wednesday. They set an "overweight" rating and a $110.00 price target on the stock. TD Securities reduced their price objective on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Jefferies Financial Group upgraded GeneDx from a "hold" rating to a "buy" rating and set a $80.00 target price on the stock in a research report on Friday, May 9th. Finally, Wells Fargo & Company cut their price target on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $92.33.

Institutional Trading of GeneDx

A number of hedge funds and other institutional investors have recently made changes to their positions in WGS. Bank of New York Mellon Corp raised its position in GeneDx by 26.6% in the fourth quarter. Bank of New York Mellon Corp now owns 40,914 shares of the company's stock valued at $3,145,000 after purchasing an additional 8,597 shares during the period. Charles Schwab Investment Management Inc. grew its position in GeneDx by 3.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 151,403 shares of the company's stock valued at $11,637,000 after acquiring an additional 4,369 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in GeneDx during the fourth quarter worth about $209,000. Arizona State Retirement System purchased a new position in shares of GeneDx in the fourth quarter valued at approximately $269,000. Finally, Raymond James Financial Inc. purchased a new position in shares of GeneDx in the fourth quarter valued at approximately $20,371,000. Institutional investors and hedge funds own 61.72% of the company's stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.